435 related articles for article (PubMed ID: 33594811)
21. Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review.
Guillo L; D'Amico F; Danese S; Peyrin-Biroulet L
J Crohns Colitis; 2021 Jul; 15(7):1236-1243. PubMed ID: 33367674
[TBL] [Abstract][Full Text] [Related]
22. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
[TBL] [Abstract][Full Text] [Related]
23. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
24. Off-label dermatologic uses of anti-TNF-a therapies.
Alexis AF; Strober BE
J Cutan Med Surg; 2005 Dec; 9(6):296-302. PubMed ID: 16699906
[TBL] [Abstract][Full Text] [Related]
25. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
26. Paradoxical Psoriasis in Children Receiving Anti-TNFα Treatment for Inflammatory/autoimmune Disease.
Rosenwasser N; Lee D; Sidbury R; Zhao Y
Paediatr Drugs; 2021 Mar; 23(2):131-141. PubMed ID: 33761130
[TBL] [Abstract][Full Text] [Related]
27. Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 Nov; 33(7):2886-2893. PubMed ID: 35694729
[TBL] [Abstract][Full Text] [Related]
28. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.
Mocci G; Marzo M; Papa A; Armuzzi A; Guidi L
J Crohns Colitis; 2013 Nov; 7(10):769-79. PubMed ID: 23453887
[TBL] [Abstract][Full Text] [Related]
29. Tumor Necrosis Factor Inhibitor-Induced Psoriasis in a Pediatric Crohn's Disease Patient Successfully Treated with Ustekinumab.
Bonomo L; de Moll EH; Li L; Geller L; Gordon MI; Dunkin D
J Drugs Dermatol; 2020 Mar; 19(3):328-331. PubMed ID: 32550694
[TBL] [Abstract][Full Text] [Related]
30. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.
Xie W; Xiao S; Huang H; Zhang Z
Front Immunol; 2022; 13():847160. PubMed ID: 35300336
[TBL] [Abstract][Full Text] [Related]
31. Biological therapy for dermatological manifestations of inflammatory bowel disease.
Zippi M; Pica R; De Nitto D; Paoluzi P
World J Clin Cases; 2013 May; 1(2):74-8. PubMed ID: 24303470
[TBL] [Abstract][Full Text] [Related]
32. Systematic review of TNFα-induced paradoxical psoriasis: Treatment outcomes of switching to alternative biologic therapies in inflammatory bowel disease patients.
Revankar R; Patel H; Rojas M; Walsh S; McGee JS
J Dermatolog Treat; 2023 Dec; 34(1):2133533. PubMed ID: 36205507
[TBL] [Abstract][Full Text] [Related]
33. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
[TBL] [Abstract][Full Text] [Related]
34. Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy.
Sridhar S; Maltz RM; Boyle B; Kim SC
Inflamm Bowel Dis; 2018 Aug; 24(9):2086-2092. PubMed ID: 29718343
[TBL] [Abstract][Full Text] [Related]
35. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
Puig L; Morales-Múnera CE; López-Ferrer A; Geli C
Dermatology; 2012; 225(1):14-7. PubMed ID: 22890275
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
37. Biologic drugs for inflammatory bowel disease.
Yanai S; Matsumoto T
Nihon Rinsho; 2017 Mar; 75(3):403-407. PubMed ID: 30566782
[TBL] [Abstract][Full Text] [Related]
38. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
39. The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?
Denadai R; Teixeira FV; Saad-Hossne R
Arq Gastroenterol; 2012; 49(2):172-6. PubMed ID: 22767007
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacology of biologic medications].
Marusić M; Mihaljević S
Acta Med Croatica; 2013 Apr; 67(2):125-30. PubMed ID: 24471295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
